



Minimal Risk IRB (Health Sciences)

1/21/2021

Submission ID number: [2013-1357-CR008](#)
Title: ORegon CHild Absenteeism due to Respiratory Disease Study
Principal Investigator: Jonathan L Temte
Point-of-contact: Shari K Barlow
IRB Staff Reviewer: Jessica Johnson

A designated MR IRB member conducted an expedited review of the above-referenced continuing review progress report form. The study was approved by the IRB member for the period of 12 months with the expiration date of 1/20/2022. The study qualified for expedited review pursuant to 45 CFR 46.110 and, if applicable, 21 CFR 56.110 and 38 CFR 16.110:

Category 9: The study meets ALL of the following criteria: (i) Categories 2 through 8 do not apply; (ii) The research is not conducted under an investigational new drug application or investigational device exemption; AND (iii) The IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified

To access the materials approved by the IRB, including any stamped consent forms and recruitment materials, please log in to your ARROW account and view the documents tab in the submission's workspace.

Please review the Investigator Responsibilities guidance (<https://kb.wisc.edu/hsirbs/page.php?id=18881>), which includes a description of IRB requirements for submitting continuing review progress reports, personnel changes, changes of protocol and reportable events.

If you have general questions, please contact the Health Sciences IRBs at 608-263-2362. For questions related to this submission, contact the assigned staff reviewer.